Search Results

Keywords: sativex

Tilray to export medical cannabis to New Zealand 

Tilray, a federally licensed cultivation company based in Nainamo, Canada, will begin exporting medical cannabis to New Zealand before the end of February. It’s the latest overseas deal for Tilray, which is owned by Seattle-based private equity firm Privateer Holdings. Both the Canadian and New Zealand governments have approved the MMJ exports, Tilray announced in […]

Read More

Brazil allows sale of cannabis-based MS drug

Brazil’s health care regulator, ANVISA, handed out the nation’s first license for the sale of a cannabis-based drug – one designed for the treatment of multiple sclerosis. According to Reuters, U.K.-based GW Pharmaceuticals PLC developed the marijuana-based oral spray, which is known internationally as Sativex. It will be marketed in Brazil as Mevatyl. ANVISA announced […]

Read More

UK to legalize CBD-based products as medicine

The United Kingdom’s top medical products regulatory authority has ruled that CBD and products containing the cannabis compound will now be treated as medicine. The announcement, however, doesn’t mean consumers will suddenly be able to buy CBD-infused products. Medicine makers will have to prove their CBD products meet safety, quality and effectiveness standards, the BBC […]

Read More

British Government to Test CBD Product

Britain’s National Health Service is set to run tests on a CBD product that’s been on the market in the United Kingdom for over a year. The test results could lead to further acceptance of medical cannabis in the U.K. and provide new opportunities for medical marijuana entrepreneurs. The NHS will be testing the MediPen, a […]

Read More

GW Pharma Boosts Production in Expectation of FDA Approval

GW Pharmaceuticals is reportedly increasing its manufacturing capacity for medical marijuana and a specific cannabis-based drug it has developed for epileptics called Epidiolex. The British company is boosting production in anticipation of getting the green light from the U.S. Food and Drug Administration next year or in early 2017 to begin widespread distribution in the United […]

Read More

Barbarians at the Gate

Powerhouse companies in other industries are eyeing the profits and potential of cannabis, laying down plans to enter – and forever change – the business.

Read More

GW Pharmaceuticals Added to Nasdaq Biotech Index

GW Pharmaceuticals, a United Kingdom-based company that develops CBD-rich treatments, has been added to the Nasdaq Biotechnology Index (NBI). The NBI tracks the performance of a set of securities traded on the exchange that are classified as biotech or pharmaceutical companies. GW Pharmaceuticals is the developer of Sativex, a cannabis-based drug that is approved in […]

Read More

From Canada to France, Many New Opportunities for US Marijuana Businesses Abroad

With 19 states legalizing marijuana for medical purposes and another two approving it for recreational use, most US cannabis businesses are content to focus on the sizable domestic market. But there are a growing number of international business opportunities for certain types of marijuana companies. A handful of countries are loosening their policies surrounding marijuana […]

Read More